1-20 of 24
Manuel Ruiz-Borrego
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study

Dejan Juric, Nicholas Turner, Aleix Prat, Stephen Chia, Eva M Ciruelos, Manuel Ruiz-Borrego, Pamela Drullinsky, Florence Lerebours, Thomas Bachelot, O. Alejandro Balbin, Mukta Joshi, Estelle Roux, Christina H Arce, Murat Akdere, Hope S Rugo
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-13-03
Published: 15 February 2022
View article
Journal Articles

Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer

Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, Adam Brufsky, Jo Chien, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A Cheong, Christian F Singer, Daniel Hunt, Navid Foruzan, Leanne McCulloch, Carlos H Barcenas
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-18-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-18-02
Published: 15 February 2022
View article
Journal Articles

Abstract P5-16-07: Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)

Lisa A. Carey, Amelia Zelnak, Hope S. Rugo, Florence Dalenc, Rita Nanda, Michael Danso, Mahasti Saghatchian, Kevin Kalinsky, Nelly Firmin, Manuel Ruiz-Borrego, Anne Favret, Jun Sun, Lee Schwartzberg, Christie Hilton, Coral Omene, Robyn Young, Sara A. Hurvitz, Eliza Harting, See Phan, Aditya Bardia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-16-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P5-16-07
Published: 15 February 2022
View article
Journal Articles

Abstract GS2-07: Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)

Kevin M Kalinsky, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori A Goldstein, Stephen KL Chia, Sukhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martin, Catherine M Kelly, Manuel Ruiz-Borrego, Miguel Gil-Gil, Claudia H Arce-Salinas, Etienne GC Brain, Eun Sook Lee, Jean-Yves Pierga, Begoña Bermejo, Manuel Ramos-Vasquez, Kyung Hae Jung, Jean-Marc Ferrero, Anne Schott, Steven Shak, Priyanka Sharma, Danika Lew, Jieling Miao, Debasish Tripathy, Lajos Pusztai, Gabriel Hortobagyi
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS2-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS2-07
Published: 15 February 2022
View article
Journal Articles

Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve

Stephen Chia, Eva M Ciruelos, Hope S Rugo, Florence Lerebours, Manuel Ruiz-Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Nicholas Turner, Ennan Gu, Christina Arce, Murat Akdere, Dejan Juric
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P1-18-08
Published: 15 February 2022
View article
Journal Articles

Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A

Eva M Ciruelos, Florence Lerebours, Hope S Rugo, Manuel Ruiz-Borrego, Pamela Drullinsky, Aleix Prat, Thomas Bachelot, Patrick Neven, Yeon Hee Park, Nicholas Turner, Dejan Juric, Ennan Gu, Christina H Arce, Murat Akdere, Stephen Chia
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-18-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P1-18-03
Published: 15 February 2022
View article
Journal Articles

Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial

Nick Turner, Hope S Rugo, Eva M Ciruelos, Manuel Ruiz-Borrego, Pamela Drullinsky, Florence Lerebours, Aleix Prat, Thomas Bachelot, Stephen Chia, Alejandro Balbin, Mukta Joshi, Estelle Roux, Christina H Arce, Murat Akdere, Dejan Juric
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD15-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD15-01
Published: 15 February 2022
View article
Journal Articles

Abstract PS10-27: A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)

Antonio Llombart-Cussac, Javier Cortés, Beatriz Bellosillo Paricio, Miguel Gil Gil, Giuseppe Curigliano, José Manuel Pérez-García, Laura Comerma Blesa, Manuel Ruíz Borrego, Enrique Espinosa, Lourdes Calvo, Begoña Bermejo, Meritxell Bellet, Federico Rojo Todo, Juan de la Haba, Vanesa Quiroga, Alessandro Minisini, Ana Santaballa, Miguel Sampayo, Andrea Malfettone, Joan Albanell
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS10-27.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS10-27
Published: 15 February 2021
View article
Journal Articles

Abstract PS10-17: Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)

José Manuel Pérez-García, Antonio Llombart-Cussac, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Serena Di Cosimo, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez-De Dueñas, Vicente Carañana, Kepa Amillano, Andrea Malfettone, Javier Cortés
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS10-17.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS10-17
Published: 15 February 2021
View article
Journal Articles

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Richard Baird, Mafalda Oliveira, Eva Maria Ciruelos Gil, Manish R Patel, Begoña Bermejo de las Heras, Manuel Ruiz-Borrego, Javier García-Corbacho, Anne Armstrong, Udai Banerji, Chris Twelves, Valentina Boni, Jason Incorvati, Peter Kabos, Adam L Cohen, Bruno de Paula, Marta Capelán Rodríguez, Judy S Wang, Christina Hernando, Alejandro Falcón Gonzalez, Ivan Victoria Ruiz, Julia Lai-Kwon, Anosheh Afghani, Christos Vaklavas, Tim Brier, Steven Fox, Bistra Kirova, Teresa Klinowska, Chris Leach, Justin PO Lindemann, Richard Mather, Rhiannon Maudsley, Christopher J Morrow, Nitharsan Sathiyayogan, Andy Sykes, Li Zhang, Erika Hamilton
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS11-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS11-05
Published: 15 February 2021
View article
Journal Articles

Abstract PS12-17: Baseline characteristics of women enrolled in the POSITIVE trial (pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer)

Ann H Partridge, Samuel M Niman, Monica Ruggeri, Fedro A Peccatori, Hatem A Azim, Jr, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Barbro Sætersdal, Judith Kroep, Ellen Warner, Virginia F Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Hideko Yamauchi, Jeong Eon Lee, Janice M Walshe, Manuel Ruíz Borrego, Halle CF Moore, Christobel Saunders, Fatima Cardoso, Snezana Susnjar, Vesna Bjelic-Radisic, Karen L Smith, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS12-17.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS12-17
Published: 15 February 2021
View article
Journal Articles

Abstract PS13-20: Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

Manuel Ruiz-Borrego, Arlene Chan, Gavin Marx, Adam Brufsky, A Jo Chien, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A García-Sáenz, Daniel Egle, Daniel Hunt, Utpal Khambholja, Leanne McCulloch, Naisargee Shah, Debu Tripathy, Carlos H Barcenas, the CONTROL Investigators
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS13-20.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS13-20
Published: 15 February 2021
View article
Journal Articles

Abstract PS2-01: Plk1 expression & efficacy of palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03)

Angel Guerrero- Zotano, Christoph Zielinski, Miguel Gil-Gil, Manuel Ruiz-Borrego, Eva M. Ciruelos, Montserrat Munoz, Begoña Bermejo, Mireia Margeli, Antonio Antón, Tibor Csöszi, Andrés García-Palomo, Ana Santaballa, Jose Luis Alonso, Antonio Fernández, Massimo Corsaro, Jesús Herranz, Paula López, Rosalia Caballero, Christiane Thallinger, Miguel Martin
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS2-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS2-01
Published: 15 February 2021
View article
Journal Articles

Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)

Kevin Kalinsky, William E Barlow, Funda Meric-Bernstam, Julie R Gralow, Kathy S Albain, Daniel Hayes, Nancy Lin, Edith A Perez, Lori J Goldstein, Stephen Chia, Subkhbinder Dhesy-Thind, Priya Rastogi, Emilio Alba, Suzette Delaloge, Miguel Martín, Miguel Gil Gil, Claudia Arce-Salinas, Etienne Brain, In Hae Park, Jean-Yves Pierga, Ana Hernandez Lluch, Manuel Ramos Vasquez, Manuel Ruiz Borrego, Kyung Hae Jung, Jean-Marc Ferrero, Anne Schott, Steve Shak, Priyanka Sharma, Danika L Lew, Jieling Miao, Debu Tripathy, Gabriel Hortobagyi, Lajos Pusztai
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): GS3-00.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-GS3-00
Published: 15 February 2021
View article
Journal Articles

Abstract P1-18-29: Neopersur: Neoadjuvant pertuzumab in a real world data population in the south of Spain

Alejandro Falcón González, Rocío Álvarez Ambite, Elisenda Llabrés Valenti, Rocío Urbano Cubero, Maria del Carmen Álamo de la Gala, Antonia Martínez Guisado, Carlos José Rodríguez González, Marta Amérigo Góngora, Encarnación González Flores, Salvador Gámez Casado, María Valero Arbizu, Alicia Quilez Cutillas, Josefina Cruz Jurado, Pedro Sánchez Rovira, Fernando Henao Carrasco, Javier Salvador Bofill, Manuel Ruiz Borrego
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P1-18-29.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P1-18-29
Published: 15 February 2020
View article
Journal Articles

Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

Miguel Martín, Christoph Zielinski, Manuel Ruíz-Borrego, Eva Carrasco, Eva Ciruelos, Montserrat Muñoz, Begoña Bermejo, Mireia Margeli, Nicholas Turner, Maribel Casas, Antonio Antón, Tibor Csöszi, Massimo Corsaro, Laura Murillo, Serafín Morales, Emilio Alba, Cynthia H Bartlett, Maria Koehler, Angel Guerrero, Zsuzsanna Kahan, Miguel Gil-Gil
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS2-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-GS2-07
Published: 15 February 2020
View article
Journal Articles

Abstract P5-14-03: Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2-positive early-stage breast cancer: Phase II CONTROL trial

Arlene Chan, Sara A Hurvitz, Gavin Marx, Manuel Ruiz-Borrego, Cynthia Farrell, Daniel Hunt, Leanne McCulloch, A Jo Chien, Debu Tripathy, Carlos H Barcenas, the CONTROL Investigators
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P5-14-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P5-14-03
Published: 15 February 2020
View article
Journal Articles

Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

José Manuel Pérez-García, Antonio Llombart-Cussac, Esther Holgado, Giuseppe Curigliano, Elena López Miranda, José Luis Alonso-Romero, Begoña Bermejo, Lourdes Calvo, Vicente Carañana, Susana de la Cruz Sánchez, María Gión Cortés, Raúl Márquez Vázquez, Aleix Prat, Manuel Ruiz Borrego, Miguel Sampayo, Miguel Àngel Seguí, Jesus Soberino, Andrea Malfettone, Peter Schmid, Javier Cortés
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-09-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-P3-09-03
Published: 15 February 2020
View article
Journal Articles

Abstract CT219: Neoadjuvant letrozole and palbociclib in stage II-IIIB HR[+]/HER2[-] breast cancer with Oncotype DX Recurrence Score® (RS) 18-25 or 26-100. Analysis of RS changes at surgery (DxCARTES trial)

Antonio Llombart Cussac, José Pérez-García, Ángel Guerrero, Begoña Bermejo, Miguel Gil, Vicente Carañana, Serafín Morales, Juan de la Haba, María Fernández, Emilio Alba, Ander Urruticoechea, Lourdes Calvo, Mireia Margeli, Antonio Antón, Manuel Ruíz Borrego, Joan Albanell, Pedro Sánchez Rovira, Meritxell Bellet, Sofia Braga, Passos Coelho, Miguel Abreu, Javier Cortés
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT219.
DOI: https://doi.org/10.1158/1538-7445.AM2019-CT219
Published: 01 July 2019
View article
Journal Articles

Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

José Manuel Pérez García, Antonio Llombart, José Luis Alonso, Begoña Bermejo, Lourdes Calvo, Vicente Carañana, Giuseppe Curigliano, Susana de la Cruz Sánchez, María Gión Cortés, Raúl Márquez Vázquez, Aleix Prat, Manuel Ruiz Borrego, Miguel Sampayo, Peter Schmid, Miguel Ángel Seguí, Javier Cortés, Esther Holgado
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT152.
DOI: https://doi.org/10.1158/1538-7445.AM2018-CT152
Published: 01 July 2018
View article